

Clinical and Epidemiological Aspects of Determining the Effectiveness of Drugs in Primary and Secondary Pulmonary Tuberculosis

Ashurov O.Sh.

otabek.ashuri@gmail.com

Bukhara State Medical Institute

Abstract: A third of the world's population is infected with *Mycobacterium tuberculosis* (MTB) and more than 9 million cases of tuberculosis (TB) are diagnosed annually, resulting in almost 2 million deaths each year (WHO., 2015). TB accounts for more than a quarter of all preventable deaths among adults in TB-endemic countries and a third of deaths among people with HIV infection. These facts make it possible to classify TB as a disease with a high mortality rate in the adult population. The scale of the TB problem is further aggravated by the evolution and global spread of *Mycobacterium tuberculosis* strains that are resistant to primary and reserve anti-TB drugs. Of particular concern are cases of drug resistance, increasing from multidrug resistance and extensive drug resistance to variants of infection for which no effective therapeutics remain

Key words: Koch bacillus, primary tuberculosis, infection, tuberculosis, morbidity, anti-tuberculosis drugs, chronic.

Tuberculosis is a socially significant infection and is one of the ten leading causes of death in the world. In this regard, the World Health Organization (WHO) has developed a strategy to eliminate tuberculosis for the period 2016-2035. The implementation of this strategy involves a thorough epidemiological assessment of the situation to identify regions and subpopulations with a high burden of disease in order to achieve targets for reducing morbidity and mortality from this infection.

Drug-resistant tuberculosis (TB) is a growing global threat. Approximately 450,000 people developed multidrug-resistant TB worldwide in 2012 and an estimated 170,000 people died from the disease. This paper describes the sociodemographic, clinical-epidemiological and bacteriological aspects of TB and correlates these features with the distribution of anti-TB drug resistance. *Mycobacterium tuberculosis* (MT) cultures and drug susceptibility testing were performed according to the BACTEC MGIT 960 method. The results demonstrated that MT strains from individuals who received treatment for TB and people who were infected with human immunodeficiency virus were more resistant to TB drugs compared to other individuals ($p < 0.05$). Approximately half of the individuals received supervised treatment, but most drug-resistant cases were positive for pulmonary TB and exhibited positive acid-fast bacilli smears, which are

complicating factors for TB control programs. Primary healthcare is the ideal level for early disease detection, but tertiary healthcare is the most common entry point for patients into the system. These factors require special attention from healthcare managers and professionals to effectively control and monitor the spread of TB drug-resistant cases.

Tuberculosis (TB) is one of the pressing problems of practical health care throughout the world. The causative agent of tuberculosis infection, *M. tuberculosis*, as an infectious agent, has killed more people than any other microbial pathogen (Daniel T.M., 2006). According to WHO, in 2012, 8.7 million new cases were registered in the world, the incidence rate was 125 per 100 thousand population (WHO, 2012). At the same time, the rise in incidence, characteristic of the last two decades, took place not only in economically backward countries, but also in developed countries of Western Europe, as well as in the USA (Onischenko G.G., 2008). This unfavorable trend is still observed today, despite the availability of effective treatment regimens and diagnostic methods (Ernst J. D. et al., 2007)

Purpose of the study: to identify the features of the epidemiological manifestations of tuberculosis and drug resistance of the pathogen to determine the possibility of eliminating the infection in the territories of the Republic of Uzbekistan.

Research objectives:

1. To study the manifestations of the epidemic process of tuberculosis in the territories of the Republic of Uzbekistan.
2. To analyze indicators of multidrug resistance of *M. tuberculosis* strains in newly diagnosed patients with respiratory tuberculosis and patients treated with anti-tuberculosis drugs in the territories of the Republic of Uzbekistan.
3. Determine the molecular genetic characteristics of *M. tuberculosis* in patients with ineffective therapy using the example of the Bukhara region.
4. To forecast the incidence of tuberculosis in the territories of the Republic of Uzbekistan to determine the prospects for eliminating the infection.

Conclusions

1. The socio-epidemiological significance of tuberculosis is currently determined by the following features: stabilization of the incidence rate at a high level (53.4 - 42.3 per 100 thousand in 2001 - 2005) with a simultaneous continued increase in mortality (from 6.4 per 100 thousand in 1999 to 11.9 per 100 thousand in 2005), an increase in the proportion of bacillary patients (from 36.2% in 1999 to 56.4% in 2005), an increase in the infection rate of children in all groups (from 20.7% in 1999 to 48.5% in 2005 in the age group up to 14 years, and, accordingly, from 50.8% to 83.6% in the age group from 15 to 18 years).
2. When studying the main factors and risk groups, it was found that men suffer from tuberculosis more often than women, accounting for 62.8% of the total number of patients. Among newly diagnosed patients, both men and women, there is a large proportion of representatives of the economically and socially active age group - from 30 to 49 years (45.6%). In the structure of patients based on social characteristics, the largest share (43.3%) is unemployed of working age.

However, among women who contracted tuberculosis in the last five years, the proportion of employees (43.8%) became higher than the proportion of non-working women (35.0%)

3. In the modern structure of foci of tuberculosis infection, foci with single diseases predominate (97.8%), formed by patients with newly diagnosed tuberculosis (72.8%), living in communal apartments (67.2%), group I epidemic burden: educated bacteria-transmitting patients living with children in unfavorable sanitary and hygienic conditions (51.3%) and under the supervision of a dispensary for one year (53.2%).

4. During the observation period from 1999 to 2005, the share of foci of drug-resistant tuberculosis increased from 17.1% to 26.7%, amounting to an average of 20.7%.

5. In the structure of outbreaks based on social characteristics, the share of outbreaks formed by persons without a fixed place of residence averaged 1999-2005, 5.4%, and the share of outbreaks formed by persons permanently residing without official registration is 3.6%. During this period, the proportion of outbreaks of these types increased: from 2.3% to 10.7%, and from 1.6% to 9.9%, respectively.

6. The most important method for detecting tuberculosis in current conditions continues to be a fluorographic examination of the population. Preventive examinations for tuberculosis should be concentrated in social groups at risk. Such groups are homeless people (detection rate is 44.4 ± 24.22 per 1000), unemployed people of working age (detection rate - 1.91 ± 0.51) and employees of private enterprises (detection rate - 1.39 ± 0.64).

7. The quality of bacterioscopic examination for tuberculosis in the general medical network was unsatisfactory. Isolation of mycobacteria by patients could only be detected in specialized anti-tuberculosis institutions and never in the general medical network. It is necessary to take urgent measures to improve the quality of bacterioscopic diagnostics in medical institutions of the general medical network.

8. Disinfection measures in the foci of tuberculosis were not carried out in full: chamber disinfection of personal belongings and bedding of patients was not carried out, which significantly reduced the value of the final disinfection.

REFERENCES

1. Al-Hajoj S, Varghese B, Shoukri MM, Al-Omari R, Al-Herbwai M, Alrabiah F, Alrajhi AA, Abuljadayel N, Al-Thawadi S, Zumla A, Zignol M, Raviglione MC, Memish Z. Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey. *Antimicrob Agents Chemother*. 2013;57:2161–2166. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
2. Araújo AK, Menezes EA, Santos CD, Cunha FA, Campelo CL. Avaliação da resistência de drogas antituberculosas no estado do Ceará no período de 2000-2002. *Rev Bras Anal Clin*. 2005;37:15–18. [[Google Scholar](#)]
3. Baptista IMFD, Oelemann MC, Opromolla DVA, Suffys PN. Drug resistance and genotypes of strains of *Mycobacterium tuberculosis* isolated from human immunodeficiency virus-

- infected and non-infected tuberculosis patients in Bauru, São Paulo, Brazil. *Mem Inst Oswaldo Cruz*. 2002;97:1147–1152. [[PubMed](#)] [[Google Scholar](#)]
4. Brito RC, Gounder C, Lima DB, Siqueira H, Cavalcanti HR, Pereira MM, Kritski AL. Resistência aos medicamentos anti-tuberculose de cepas de *Mycobacterium tuberculosis* isoladas de pacientes atendidos em hospital geral de referência para tratamento de AIDS no Rio de Janeiro. *J Bras Pneumol*. 2004;30:425–432. [[Google Scholar](#)]
 5. Coelho AGV, Zamarioli LA, Telles MA, Ferrazoli L, Waldman EA. A study of multidrug-resistant tuberculosis in risk groups in the city of Santos, São Paulo, Brazil. *Mem Inst Oswaldo Cruz*. 2012;107:760–766. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
 6. Collins CH, Grange JM, Yates MD. Identification of species. In: Collins CH, Grange JM, Yates MD, editors. *Tuberculosis bacteriology: organization and practice*. 2nd. Butterworth-Heinemann; Oxford: 1997. pp. 69–97. [[Google Scholar](#)]
 7. CT/GTD - Comissão de Tuberculose, Grupo de Trabalho das Diretrizes para Tuberculose III Brazilian Thoracic Association Guidelines on Tuberculosis. III Diretrizes para Tuberculose da Sociedade Brasileira de Pneumologia e Tisiologia. *J Bras Pneumol*. 2009;35:1018–1048. [[PubMed](#)] [[Google Scholar](#)]
 8. Souza MB de, Antunes CMF, Garcia GF. Perfil de sensibilidade e fatores de risco associados à resistência do *Mycobacterium tuberculosis* em centro de referência de doenças infecto-contagiosas de Minas Gerais. *J Bras Pneumol*. 2006;32:430–437. [[PubMed](#)] [[Google Scholar](#)]
 9. Fandinho FCO, Kritski AL, Hofer C, Conde H, Jr, Ferreira RMC, Silva MG, Fonseca LS. Drug resistance patterns among hospitalized tuberculous patients in Rio de Janeiro, Brazil, 1993-1994. *Mem Inst Oswaldo Cruz*. 1999;94:543–547. [[PubMed](#)] [[Google Scholar](#)]
 10. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. *Thorax*. 2006;61:158–163. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
 11. French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V, Abubakar I. The association between HIV and antituberculosis drug resistance. *Eur Respir J*. 2008;32:718–725. [[PubMed](#)] [[Google Scholar](#)]
 12. García VD. Rapid detection of resistance in *Mycobacterium tuberculosis*: a review discussing molecular approaches. *Clin Microbiol Infect*. 2003;9:349–359. [[PubMed](#)] [[Google Scholar](#)]
 13. Gazetta CE, Vendramini SHF, Ruffino-Netto A, Oliveira MRC, Villa TCS. Estudo descritivo sobre a implantação da estratégia de tratamento de curta duração diretamente observado no controle da tuberculose em São José do Rio Preto e seus impactos (1998-2003) *J Bras Pneumol*. 2007;33:192–198. [[PubMed](#)] [[Google Scholar](#)]
 14. Giampaglia CMS, Martins MC, Vieira GB, Vinhas SA, Telles MA, Palaci M, Marsico AG, Hadad DJ, Fonseca LS, Kritski A. Multicentre evaluation of an automated BACTEC 960 system for susceptibility testing of *Mycobacterium tuberculosis*. *Int J Tuberc Lung Dis*. 2007;11:986–991. [[PubMed](#)] [[Google Scholar](#)]
 15. Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulabhal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. *Lancet*. 2009;373:1861–1873. [[PubMed](#)] [[Google Scholar](#)]

16. IBGE - Instituto Brasileiro de Geografia e Estatística . *Cidades*. 2010. <http://ibge.gov.br/cidadesat/topwindow.htm?1> [Google Scholar]
17. Kritski AL. Emergência de tuberculose resistente: renovado desafio. *J Bras Pneumol*. 2010;36:157–158. [PubMed] [Google Scholar]
18. Kruuner A, Yates MD, Drobniowski FA. Evaluation of MGIT 960-based antimicrobial drugs with drug-resistant clinical strains of *M. tuberculosis*. *J Clin Microbiol*. 2006;44:811–818. [PMC free article] [PubMed] [Google Scholar]
19. Lawn SD, Zumla AI. Tuberculosis. *Lancet*. 2011;378:57–72. [PubMed] [Google Scholar]
20. Liu Q, Zhu L, Shao Y, Song H, Li G, Zhou Y, Shi J, Zhong C, Chen C, Lu W. Rates and risk factors for drug resistance tuberculosis in northeastern China. *BMC Public Health*. 2013;13:1171–1171. [PMC free article] [PubMed] [Google Scholar]
21. Lobacheva T, Asikainen T, Giesecke J. Risk factors for developing tuberculosis in remand prisons in St. Petersburg, Russia - a case-control study. *Eur J Epidemiol*. 2007;22:121–127. [PubMed] [Google Scholar]
22. Marais BJ, Mlambo CK, Rastogi N, Zozio T, Duse AG, Victor TC, Marais E, Warren RM. Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. *J Clin Microbiol*. 2013;51:1818–1825. [PMC free article] [PubMed] [Google Scholar]
23. Marques M, Cunha EAT, Ruffino-Netto A, Andrade SMO. Perfil de resistência de *Mycobacterium tuberculosis* no estado de Mato Grosso do Sul, 2000-2006. *J Bras Pneumol*. 2010;36:224–231. [PubMed] [Google Scholar]
24. Martin V, Gonzáles P, Caylà JA, Mirabent J, Cañellas J, Pina JM, Miret P. Case finding of pulmonary tuberculosis on admission to a penitentiary center. *Tuber Lung Dis*. 1994;75:49–53. [PubMed] [Google Scholar]
25. Melo FAF, Afiune JB, Neto JI, Almeida EA, Spada DTA, Antelmo ANL, Cruz ML. Aspectos epidemiológicos da tuberculose multirresistente em serviço de referência na cidade de São Paulo. *Rev Soc Bras Med Trop*. 2003;36:27–34. [PubMed] [Google Scholar]
26. Mendes JM, Lourenço MC, Ferreira RMC, Fonseca LS, Saad MHF. Resistência a drogas em cepas de *Mycobacterium tuberculosis* isoladas de amostras de escarro de pacientes ambulatoriais sintomáticos - Complexo de Manguinhos, Rio de Janeiro, Brasil. *J Bras Pneumol*. 2007;33:579–582. [PubMed] [Google Scholar]
27. Micheletti VCD, Moreira JS, Ribeiro MO, Kritski AL, Braga JU. Tuberculose resistente em pacientes incluídos no II Inquérito Nacional de Resistência aos Fármacos Antituberculose realizado em Porto Alegre, Brasil. *J Bras Pneumol*. 2014;40:155–163. [PMC free article] [PubMed] [Google Scholar]
28. Miller N, Cleary T, Kraus G, Young AK, Spruill G, Hnatyszyn HJ. Rapid and specific detection of *Mycobacterium tuberculosis* from acid-fast bacillus smear-positive respiratory specimens and BacT/Alert MP culture bottles by using fluorogenic probes and real-time PCR. *J Clin Microbiol*. 2002;40:4143–4147. [PMC free article] [PubMed] [Google Scholar]
29. Motta MSC, Villa TCS, Golub J, Kritski AL, Ruffino-Netto A, Silva DF, Harter RG. Access to tuberculosis diagnosis in Itaboraí city, Rio de Janeiro, Brazil: the patient's point of view. *Int J Tuberc Lung Dis*. 2009;13:1137–1141. [PMC free article] [PubMed] [Google Scholar]

30. MS/SVS - Ministério da Saúde/Secretaria de Vigilância em Saúde Brasil . *Portaria/MS 1.339/1999, Regulamento da Previdência Social*. MS; Brasília: 1999. [[Google Scholar](#)]
31. MS/SVS/DVE - Ministério da Saúde/Secretaria de Vigilância em Saúde/Departamento de Vigilância Epidemiológica Brasil . *Manual nacional de vigilância laboratorial da tuberculose e ou-tras micobactérias*. MS/SVS/DVE; Brasília: 2008. 436 [[Google Scholar](#)]
32. MS/SVS/DVE - Ministério da Saúde/Secretaria de Vigilância em Saúde/Departamento de Vigilância Epidemiológica Brasil . *Manual de recomendações para o controle da tuberculose no Brasil*. MS/SVS/DVE; Brasília: 2011. 284 [[Google Scholar](#)]
33. Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant. *Trends Genet*. 2013;29:160–169. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
34. Parrish NM, Carroll KC. Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings. *J Clin Microbiol*. 2011;49:772–776. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
35. Pereira AM. *Georreferenciamento e genotipagem de Mycobacterium tuberculosis isolados de pacientes atendidos na cidade de Goiânia - GO pelo método de MIRU-VNTR*. Universidade Federal de Goiás; Goiânia: 2012. 94 [[Google Scholar](#)]
36. Ponce MAZ, Wysocki AD, Scatolin BE, Andrade RLP, Arakawa T, Ruffino-Netto A, Monroe AA, Scatena LM, Vendramini SHF, Villa TCS. Diagnóstico da tuberculose: desempenho do primeiro serviço de saúde procurado em São José do Rio Preto, São Paulo, Brasil. *Cad Saude Publica*. 2013;29:945–954. [[PubMed](#)] [[Google Scholar](#)]
37. Reyes H, Coninx R. Pitfalls of tuberculosis programmes in prisons. *BMJ*. 1997;31:1447–1450. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
38. Rozman LM, Santo AH, Rozman MA. Resistência do *Mycobacterium tuberculosis* às drogas em pacientes HIV+ em cinco municípios da Baixada Santista, São Paulo, Brasil. *Cad Saude Publica*. 2007;23:1051–1059. [[PubMed](#)] [[Google Scholar](#)]
39. Rüsç-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing *Micobacterium tuberculosis* to classical second-line drugs and newer antimicrobial. *J Clin Microbiol*. 2006;44:688–692. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
40. Said HM, Kock MM, Ismail NA, Baba K, Omar SV, Osman AG, Hoosen AA, Ehlers MM. Comparison between the BACTEC MGIT 960 system and the agar proportion method for susceptibility testing of multidrug resistant tuberculosis strains in a high burden setting of South Africa. *BMC Infect Dis*. 2012;12:369–369. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
41. Santos MLSSG, Ponce MAZ, Vendramini SHF, Villa TCS, Santos NSGM, Wysocki AD, Kuyumijian FG, Gazetta CE. A dimensão epidemiológica da coinfeção TB/HIV. *Rev Lat Am Enfermagem*. 2009;17:683–688. [[PubMed](#)] [[Google Scholar](#)]
42. SES/CCD/CVE/DCT - Secretaria de Estado da Saúde/Coordenadoria de Controle de Doenças/Centro de Vigilância Epidemiológica Prof Alexandre Vranjac/Divisão de Controle da Tuberculose Brasil . *TB-WEB - Sistema Estadual de Notificação da Tuberculose*. 2008. http://cve.saude.sp.gov.br/htm/TB/mat_tec/manuais/DvTBC_TBWEB_2_008.pdf [[PubMed](#)] [[Google Scholar](#)]
43. SES/CVE/DCT - Secretaria de Estado da Saúde/Centro de Vigilância Epidemiológica Prof Alexandre Vranjac/Divisão de Controle da Tuberculose Brasil . *TB em números*. Secretaria

de Estado da Saúde; São Paulo: 2008. <http://cve.saude.sp.gov.br/indicador.htm> [PubMed] [Google Scholar]

44. SES/CVE/DCT - Secretaria de Estado da Saúde/Centro de Vigilância Epidemiológica Prof Alexandre Vranjac/Divisão de Controle da Tuberculose Brasil . *Relatório de oficina realizada nos dias 17 e 18 de junho/2013 com os GVEs e municípios para discussão dos casos de tuberculose ocorridos em profissionais de saúde e da educação*. 2013. http://cve.saude.sp.gov.br/htm/cve_tb.html [Google Scholar]
45. SES-SP/CVE/DT - Secretaria do Estado da Saúde de São Paulo/Centro de Vigilância Epidemiológica Prof Alexandre Vranjac/Divisão de Tuberculose . *Manual de orientação para coleta de amostras de escarro e outros materiais para baciloscopia e cultura para diagnóstico e controle da tuberculose*. SES-SP; São Paulo: 2002. 26 [Google Scholar]
46. SMPGE - Secretaria Municipal de Planejamento e Gestão Estratégica . *Conjuntura econômica*. SMPGE; São José do Rio Preto: 2013. 28th. 91 [Google Scholar]
47. SMSH - Secretaria Municipal de Saúde e Higiene de São José do Rio Preto . *Controle de tuberculose ARE/VE. Situação da tuberculose em São José do Rio Preto*. SMSH; São José do Rio Preto: 2009. [Google Scholar]
48. Talip BA, Sleator RD, Lowery CJ, Dooley JS, Snelling WJ. An update on global tuberculosis (TB) *Infect Dis (Auckl)* 2013;6:39–50. [PMC free article] [PubMed] [Google Scholar]
49. Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, Dettoni VV, Rocha LMC, Debanne S, Talbot E, Dietze R. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2001;5:321–328. [PubMed] [Google Scholar]
50. Valença MS, Rocha JZ, Ramis IB, Carrion LL, Madruga C, Macedo MB, Scaini CJ, Von Groll A, Silva PEA. Improving tuberculosis control through the partnership between university and the health system. *Rev Soc Bras Med Trop*. 2012;45:491–495. [PubMed] [Google Scholar]
51. Vendramini SHF, Santos NSGM, Santos MLSG, Chiaravalloti-Neto F, Ponce MAZ, Gazetta CE, Villa TCS, Netto AR. Análise espacial da co-infecção tuberculose/HIV: relação com níveis socioeconômicos em município do sudeste do Brasil. *Rev Soc Bras Med Trop*. 2010;43:536–541. [PubMed] [Google Scholar]
52. Vieira RCA, Fregona G, Palaci M, Dietze R, Maciel ELN. Perfil epidemiológico dos casos de tuberculose multirresistente do Espírito Santo. *Rev Bras Epidemiol*. 2007;10:56–65. [Google Scholar]
53. Wang X, Fu Q, Li Z, Chen S, Liu Z, Nelson H, Yang Q, Jia Z, Dye C. Drug-resistant tuberculosis in Zhejiang Province, China, 1999-2008. *Emerg Infect Dis*. 2012;18:496–498. [PMC free article] [PubMed] [Google Scholar]
54. WHO - World Health Organization . *Global tuberculosis control: WHO report 2011*. WHO; Geneva: 2011. 246 [Google Scholar]
55. WHO - World Health Organization . *Global tuberculosis control: WHO report 2013*. WHO; Geneva: 2013. 304 [Google Scholar]
56. Zaman K, Rahim Z, Yunus M, Arifeen S, Baqui A, Sack D, Hossain S, Banu S, Islam MA, Ahmed J, Breiman R, Black R. Drug resistance of *Mycobacterium tuberculosis* in selected

urban and rural areas in Bangladesh. *Scand J Infect Dis.* 2005;37:21–26. [[PubMed](#)] [[Google Scholar](#)]

57. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. *N Engl J Med.* 2013;368:745–755. [[PubMed](#)] [[Google Scholar](#)]